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Osteoarthritis is a complicated clinical disorder affected by genetic 
predisposition, ageing and mechanical stress. In this study, we 
compared the effects of various anti-inflammatory analgesics on 
mechanical stress-induced inflammation in SW982 cells, a synovial 
sarcoma cell line. As an in vitro model of synovitis in osteoarthritis, 
SW982 cells were exposed to mechanical stress for 48 h by shaking 
with hydroxyapatite that simulates intraarticular microscopic debris, 
and the effects of anti-inflammatory analgesics such as 
acetaminophen, ketoprofen, triamcinolone acetonide, celecoxib and 
neurotropin on various inflammatory mediators were examined. The 
expression of integrin α5β1 was significantly increased by mechanical 
stress. Mechanical stress accelerated phosphorylation of NF-kB, 
which was suppressed by celecoxib alone among the analgesics tested. 
The concentrations of tumor necrosis factor-α (TNF-α) and matrix 
metalloproteinase-3 (MMP-3) in the medium were increased by 




acetaminophen, triamcinolone acetonide, and neurotropin. The 
prostaglandin E2 (PGE2) concentration in the medium was increased 
by mechanical stress, which was significantly suppressed by 
acetaminophen, ketoprofen, and celecoxib. Thus, acetaminophen 
showed the widest range of suppression for the inflammatory 
mediators such as TNF-α, MMP-3 and PGE2 secreted to the medium, 
suggesting that acetaminophen is a promising drug for controlling 
mechanical stress-induced synovitis in osteoarthritis. 
 






Osteoarthritis (OA) is an age-related degenerative disease that 
affects various joints of the whole body, including knee and hip joints 
(1). In this disease, synovitis occurs at an early stage and the 
cartilage is worn out by mechanical stress (MS) over time. In Japan, 
the incidence of this disease is increasing with the increase in elderly 
population. Hence, OA is a common disease in orthopedic clinics.  
A joint is covered with a capsule lined by a synovial 
membrane, and the joint space surrounded by synovial membrane is 
filled with synovial fluid. Additionally, the epiphysis is covered with 
articular cartilage, which is composed of chondrocytes and 
extracellular matrix (ECM). However, the cellular component is 
limited while the ECM constitutes approximately 95% of the total 
space of cartilage. The ECM is mainly composed of proteoglycan, 
collagen, and hyaluronic acid with embedded water molecules (1). 
Nerves, blood vessels, and lymph vessels do not exist in the cartilage; 




transported effectively to cells at the injured site. Consequently, 
natural restoration of cartilage is difficult (2). 
In OA, degeneration of cartilage, abrasion of subchondral 
bone, production of matrix metalloproteinase (MMP) and synovial 
inflammation are induced by MS which is accelerated by obesity, 
trauma and intraarticular microscopic debris (3,4,5). It is a 
complicated condition in which the disease state is influenced by 
various factors such as ageing, MS, cartilage hypertrophy, cytokines 
secreted under inflammation, and genetic predisposition. In this 
disease, activated T cells invade the synovial membrane and produce 
cytokines including interleukin (IL)-17 thereby inducing synovitis. 
Proliferated synovium produces inflammatory cytokines such as 
tumor necrosis factor-α (TNF-α), IL-1, and IL-6. Receptor activator of 
nuclear factor-κB (NF-κB) ligand (RANKL) is induced together with 
IL-17 to activate osteoclasts (6). A series of the above cellular actions 
lead to the formation of a granulation tissue called pannus which 




result, bone resorption is accelerated by proteolytic enzymes such as 
MMP-3 (7, 8).  
Anti-inflammatory analgesics are used to alleviate pain and 
inflammation in OA. Tanaka et al. utilized primary cultured synovial 
cells (synoviocytes) obtained from OA patients and treated with IL-13 
as an in vitro model of synovitis (9). However, to the best of our 
knowledge, there had been no report of an MS-induced synovitis 
model until our recent report (10) even though MS plays an essential 
role in the exacerbation of synovitis in OA. Therefore, we developed 
an MS-induced synovitis model in vitro by shaking a cultured human 
synovial sarcoma cell line (SW982) in the presence of hydroxyapatite 
as a simulator of intraarticular microscopic debris (10). The current 
study aimed at comparing the effects of various anti-inflammatory 
analgesics on the inflammatory mediators in our MS-induced 






Materials and methods 
1. Materials and cell culture 
 We purchased a human synovial sarcoma cell line (SW982) (11) from 
the ATCC (Manassas, VA, USA). Dulbecco's modified Eagle medium 
high glucose (D-MEM high glucose) was purchased from Wako Pure 
Chemical Industries, Ltd., (Osaka, Japan), and fetal bovine serum 
(FBS) was purchased from Sigma Aldrich Co. (Tokyo, Japan). We 
cultured SW982 cells in D-MEM high glucose containing 10% FBS 
under humidified conditions at 37 °C, with 5% CO2. Hydroxyapatite 
(HA) in the form of Micro-SHAp (IHM-10010) was purchased from 
Sofsera Co., Ltd. Japan, and a mini-shaker for micro plates (PSU-2T) 
was purchased from Funakoshi Co., Ltd. Japan. The following 
reagents were purchased from FUJIFILM Wako Pure Chemical 
Corporation (Japan): acetaminophen (015-13942), ketoprofen (115-
00381), triamcinolone acetonide (209-10961), celecoxib (032-24841) 
and neurotropin (874420). Injection Solution 3.6 units were 




2. MS exposure 
 SW982 cells were cultured for 24 h in a CO2 incubator and exposed 
for 48 h to MS that constitutes the following two factors. First, MS 
was induced by the addition of 5 µg/mL HA to mimic intraarticular 
microscopic debris that induce cartilage and bone destruction in OA. 
Second, MS was induced by shaking culture plates at 1,000 rpm with 
2 mm of amplitude as described previously (10). 
 
3. Evaluation of integrin α5β1 expression by fluorescence 
immunocytochemical staining 
 To evaluate integrin α5β1 receptor expression, 1 × 104 cells in 1 mL 
medium were seeded to 2-well chamber slide glasses and cultured for 
24 h followed by exposure to MS for 48 h. The cells were reacted with 
Anti-Integrin Alpha V + beta1 Antibody (bs-2016R, Bioss Antibodies 
Inc. USA) at room temperature for 2 h. Subsequently, the cells were 
reacted with secondary (TRIC-conjugated anti-rabbit IgG, A 21428, 




(bisbenzimide H33342, Wako Pure Chemical Corporation, Japan) for 
1 h followed by fluorescence analysis using a microscope (BX-X700, 
Keyence, Japan). 
 
4. Cell culture with anti-inflammatory analgesics 
For analysis of NF-kB phosphorylation and determination of TNF-
a, MMP-3 and PGE2 in the medium, cells (3 × 105）in 1 mL 
medium were seeded to 6-well plates and cultured for 24 h. The 
medium was replaced with either standard culture medium or that 
containing 50 µM acetaminophen, 50 µM ketotifen, 10 µM 
triamcinolone acetonide, 10 µM celecoxib or neurotropin at 3.6 x 
10-3 N.U. in the presence of 5 µg/mL HA. The concentrations of the 
analgesics were decided based on the effective plasma 
concentrations for clinical use. Cells were cultured for further 48 h 
under MS loading. 
 





Cells (3 × 105) in 1 mL medium were seeded to 6-well plates and 
cultured for 24 h. After changing the medium to that containing 5 
µg/mL HA and each of the anti-inflammatory analgesics, cells were 
subjected to MS for 48 h. Subsequently, the ratios of phosphorylated 
NF-κB p65 to total NF-κB P65 in the cell lysates were determined 
using the Instant One ELISA Kit (Thermo-Fisher Scientific Co., Ltd. 
Japan). Absorbance was measured at 450 nm in a microplate reader. 
 
6. Measurements of TNF-α, MMP-3, and PGE2 
Cells (3 x 105) in 1 mL medium were seeded to 6-well plates and 
cultured for 24 h. After replacing the medium with that containing 5 
µg/mL HA and each of the anti-inflammatory analgesics, cells were 
subjected to MS for 48 h. The concentrations of TNF-α, MMP-3, and 
PGE₂ in culture supernatants were determined using the Quantikine 
ELISA kit (R&D Systems) by measuring the absorbance at 450 nm in 






Experimental results are expressed as the mean ± standard error 
(mean ± SEM, n = 7–16). The luminance in the immunocytochemical 
staining was analyzed using Student's t-test, and the data for the MS 
and control (untreated) groups were analyzed using an ANOVA-








1. Expression of α5β1 after exposure to MS 
Quantification of α5β1 protein expression in SW982 cells by 
luminance/area revealed that the expression of α5β1 protein was 
significantly higher in the MS group (91.6 ± 6.6) than in the control 
group (39.8 ± 9.1) (p < 0.01) (Figure 1). 
 
2. Effect of anti-inflammatory analgesics on MS-induced NF-κB 
phosphorylation 
Phosphorylated NF-κB is an active form of NF-κB and induce various 
inflammatory reactions. The ratio of phosphorylated NF-κB to total 
NF-κB in the MS group (0.94 ± 0.08) was higher than that in the 
control group (0.51 ± 0.05) (p > 0.01) (Figure 2). Celecoxib treatment 
under MS loading significantly suppressed the ratio to 0.56 ± 0.09 
when compared to MS alone (p < 0.01).  
 





The level of TNF-α in the medium was significantly increased in the 
MS group (5.14 ± 0.52 pg/mL) compared to the control group (2.53 ± 
0.25 pg/mL) (p < 0.01) (Figure 3). Treatment under MS loading with 
acetaminophen, triamcinolone acetonide and neurotropin suppressed 
TNF-α to 2.45 ± 0.41 pg/mL (p < 0.05), 1.59 ± 0.28 pg/mL (p < 0.01), 
and 2.45 ± 0.51 pg/mL (p < 0.05), respectively, when compared to MS 
alone. Conversely, TNF-α was significantly increased in the celecoxib-
treated group (9.43 ± 1.68 pg/mL) when compared to MS alone (p < 
0.01). 
 
4. Effect of anti-inflammatory analgesics on MS-induced MMP-3 
secretion 
Figure 4 shows the concentrations of MMP-3 in the medium, a 
marker of joint destruction, after exposure for 48 h to MS in the 
presence of anti-inflammatory analgesics. There was a significant 




compared to the control group (3.77 ± 0.14 pg/mL) (p < 0.01). 
Treatment under MS loading with acetaminophen, triamcinolone 
acetonide and neurotropin significantly suppressed MMP-3 to 3.50 ± 
0.39 pg/mL (p < 0.01), 2.70 ± 0.29 pg/mL (p < 0.01) and 3.92 ± 0.55 
pg/mL (p < 0.01), respectively, when compared to MS alone. 
 
5. Effect of anti-inflammatory analgesics on MS-induced PGE2 
secretion 
Figure 5 shows the PGE2 concentrations in the medium after 
exposure for 48 h to MS in the presence of anti-inflammatory 
analgesics. PGE2 in the medium was significantly increased in the 
MS group (2,732 ± 124 pg/mL) compared to the control group (1,712 ± 
213 pg/mL) (p < 0.01). Treatment under MS loading with 
acetaminophen, ketoprofen and celecoxib significantly suppressed 
PGE2 to 1,871 ± 328 pg/mL (p < 0.01), 265 ± 30 pg/mL (p < 0.01), and 






Table 1 summarizes the effects of anti-inflammatory 
analgesics tested in the current study on the secretion of TNF-α, 
MMP-3 and PGE2, as indicators of inflammation, joint degradation 
and pain, respectively. Among the drugs tested, acetaminophen alone 
suppressed all of the three inflammatory mediators, suggesting that 
acetaminophen seems to be a well-balanced drug for relieving the 
symptoms of OA. This is the first report that focused on the effects of 
anti-inflammatory analgesics on experimental synovitis in vitro. 
Acetaminophen has both an analgesic effect and a weak 
cyclooxygenase (COX) antagonism, but the detailed mechanism 
remains unknown (12). Ketoprofen and celecoxib, which are non-
steroidal anti-inflammatory drugs (NSAIDs), inhibit the activity of 
COX and prostaglandin synthesis, especially PGE2, an agent for 
enhancing inflammation and pain (13). Ketoprofen is mainly used in 
pain relief patches in Japan (14). Celecoxib acts as a COX-2 selective 




acetonide, a corticosteroid, inhibits the activation of mitogen-
activated protein kinase (MAPK) and suppresses the activation of 
phospholipase A2 (PLA2) and subsequently AP-1 and NF-κB. (15, 16, 
17). Analgesic adjuvant (biological tissue extract) neurotropin, a non-
opioid, non-COX inhibiting agent, is clinically used in Japan (18). 
It has been reported that chronic inflammation is caused by 
damage-associated molecular patterns (DAMPs), which are 
biomolecules released from injured tissues and cells (19). In OA, the 
intraarticular microscopic debris generated by cartilage and bone 
destruction become DAMPs, which lead to chronic synovitis and 
accelerate cartilage and bone destruction (20). The synovium contains 
various types of cells such as osteoclasts, fibroblasts, macrophages, T 
cells, and B cells. SW982 cells used in the present study are derived 
from synovial fibroblasts and have been reported to be useful for 
analyses of inflammatory cytokines and MMPs in synovitis (21).  
Integrin α5β1, a membrane receptor that binds to ECM and 




proteolyzed by MMP-3 and binds to integrin α5β1, thereby activating 
tyrosine kinases such as integrin-linked kinase (ILK) and focal 
adhesion kinase (FAK). Fibronectin is therefore involved in cell 
proliferation, differentiation, and neovascularization in OA (24). 
Thus, it is possible that MS-induced activation of the integrin 
receptors (Figure 1) triggers inflammatory signals through NF-κB, 
(Figure 2) thereby enhancing production of TNF-α (Figure 3) and 
MMP-3 (Figure 4). Furthermore, it is possible to speculate that MS 
activates arachidonic acid cascade that leads to PGE2 production 
(Figure 5). Further studies are needed to test these possibilities.  
We found that MS-induced activation of NF-κB was not 
significantly suppressed by the agents except celecoxib (Figure 2). 
This finding may be explained by involvement of an alternative 
transcription factor other than NF-κB, for example C/EBPb, which 
may serve as the target of some analgesics. In chondrocytes in OA, 
tissue damage may occur by various cytokines, including IL-1b and 




on chondrocytes (3, 26).  
OA is a chronic inflammatory disease with a long clinical 
course. As an extrapolation of an epidemiological study in Japan, it 
was assumed that 25.3 million people aged 40 years and older, about 
one fourth of the total Japanese population, would be affected by 
radiographic knee OA (27). According to the evidence-based expert 
consensus guidelines based on Osteoarthritis Research Society 
International (OARSI) formulated in 2012, it is strongly 
recommended that treatment of knee OA involve combined drug and 
non-drug therapy (28, 29, 30). The guideline recommends anti-
inflammatory analgesics for OA patients. Although NSAIDs are 
recommended for OA, their side effects should be carefully monitored. 
In this regard, acetaminophen should be considered besides NSAIDs 
because acetaminophen is a relatively safe drug particularly for 
elderly patients who often have prescription for multiple drugs. Oral 
NSAIDs sometimes cause severe complications including peptic 




Japan, NSAIDs are often used in pain relief patches. Intraarticular 
injection of adrenal corticosteroids may be used mainly when oral 
medications are not effective. However, four or more treatments in a 
year are not usually recommended (28).  
In conclusion, the present study using a human synovial 
sarcoma cell line (SW982 cells) as a model of MS-induced synovitis 
demonstrated that acetaminophen suppressed the mediators involved 
in inflammation, joint destruction and pain (Table 1), suggesting that 
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Legends for figures 
Fig. 1 Effect of MS on integrin α5β1 expression  
SW982 cells (1 x 104) were seeded to 2-well chamber slide glasses and 
cultured for 24 h followed by exposure to MS for 48 h. Fluorescence 
immunocytochemical staining was conducted to detect cell surface 
integrin α5β1. Data are represented as the mean ± SEM (n = 10), 
Student’s t-test, **p < 0.01.  
 
Fig. 2 Effect of anti-inflammatory analgesics on MS-induced NF-κB 
activation 
SW982 cells (3 x 105) seeded to 6-well plates were cultured for 24 h 
followed by exposure to MS for 48 h in the absence or presence of each 
anti-inflammatory analgesic. Cell lysates were analyzed to determine 
the ratios of phosphorylated NF-kB p65 to total NF-kB p65 as 
described in Methods. Data were obtained from the indicated 
numbers of wells from 4 independent culture experiments, which are 




0.01 vs. MS. 
NF-κB: nuclear factor kappa B; MS: mechanical stress; AAP: 
acetaminophen; KET: ketoprofen; CBX: celecoxib; TA: triamcinolone 
acetonide; NTP: neurotropin 
 
Fig. 3 Effect of anti-inflammatory analgesics on MS-induced TNF-α 
secretion 
SW982 cells (3 x 105) seeded to 6-well plates were cultured for 24 h 
followed by exposure to MS for 48 h in the absence or presence of each 
anti-inflammatory analgesic. Supernatants were analyzed by ELISA 
to determine the concentrations of TNF-α as described in Methods. 
Data were obtained from the indicated numbers of wells from 4 
independent culture experiments, which are represented as the mean 
± SEM (n = 9–13), **p < 0.01, *p < 0.05, #p < 0.05 vs. MS. TNF-α: 
tumor necrosis factor alpha; MS: mechanical stress; AAP: 
acetaminophen; KET: ketoprofen; CBX: celecoxib; TA: triamcinolone 





Fig. 4 Effect of anti-inflammatory analgesics on MS-induced MMP-3 
secretion 
SW982 cells (3 x 105) seeded to 6-well plates were cultured for 24 h 
followed by exposure to MS for 48 h in the absence or presence of each 
anti-inflammatory analgesic. Supernatants were analyzed by ELISA 
to determine the concentrations of MMP-3 as described in Methods. 
Data were obtained from the indicated numbers of wells from 4 
independent culture experiments, which are represented as the mean 
± SEM (n = 7–14), **p < 0.01, ##p < 0.01 vs. MS. MMP-3: matrix 
metalloproteinase-3; MS: mechanical stress; AAP: acetaminophen; 
KET: ketoprofen; CBX: celecoxib; TA: triamcinolone acetonide; NTP: 
neurotropin 
 
Fig. 5 Effect of anti-inflammatory analgesics on MS-induced PGE2 
secretion 




followed by exposure to MS for 48 h in the absence or presence of each 
anti-inflammatory analgesic. Supernatants were analyzed by ELISA 
to determine the concentrations of PGE2 as described in Methods. 
Data were obtained from the indicated numbers of wells from 4 
independent culture experiments, which are represented as the mean 
± SEM (n = 12–16), **p < 0.01, ##p < 0.01 vs. MS. PGE2: 
prostaglandin E2; MS: mechanical stress; AAP: acetaminophen; KET: 






Table 1. Effect of various anti-inflammatory analgesics on the 
inflammatory mediators in the medium. Significant differences are 






 TNF-α MMP-3 PGE2 
Acetaminophen ↓ ↓↓ ↓↓ 
Ketoprofen   ↓↓ 
Celecoxib ↑↑  ↓↓ 
Triamcinolone 
Acetonide 
↓↓ ↓↓  
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